News Releases

2012

09/04/2012 BioSante Pharmaceuticals Announces Positive LibiGel® Phase III Safety Data Review and Decision to Conclude the Safety Study
08/30/2012 BioSante Pharmaceuticals, Inc. to Present at Stifel Nicolaus Healthcare Conference and Rodman & Renshaw Global Investment Conference
08/20/2012 BioSante Pharmaceuticals Closes $3,475,000 Registered Direct Offering
08/17/2012 BioSante Pharmaceuticals to Raise $3,475,000 in Registered Direct Offering
08/01/2012 BioSante Pharmaceuticals Reports Second Quarter Financial Results and Pipeline Update
06/19/2012 BioSante Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Listing Requirement
06/11/2012 BioSante Pharmaceuticals Announces New LibiGel® Phase III Efficacy Trials
06/04/2012 BioSante Pharmaceuticals, Inc. to Present at Jefferies Global Healthcare Conference
05/31/2012 BioSante Pharmaceuticals Announces Reverse Stock Split In Order To Maintain NASDAQ Listing
05/08/2012 BioSante Pharmaceuticals Reports First Quarter Financial Results
04/17/2012 BioSante Pharmaceuticals, Inc. to Present at BioCentury Future Leaders in the Biotech Industry Conference
03/20/2012 BioSante Pharmaceuticals Announces Positive Pill-Plus™ Data Presentation
03/13/2012 BioSante Pharmaceuticals Reports Financial Results for 2011 and Corporate Highlights
03/09/2012 BioSante Pharmaceuticals, Inc. to Present at Roth Health Care Conference
03/05/2012 BioSante’s Prostate Cancer Vaccine Resulted in Stable Disease in Over 50% of Patients in Newly Published Study
02/27/2012 BioSante’s Pancreas Cancer Vaccine Shows over 60% Survival Increase in Newly Presented Study
02/23/2012 BioSante Pharmaceuticals, Inc. to Present at Citi 2012 Global Health Care Conference
02/16/2012 BioSante Exchanges $4 Million Aggregate Principal Amount of Convertible Senior Notes for 4.5 Million Shares of Common Stock
02/15/2012 BioSante Pharmaceuticals Announces FDA Approval for Testosterone Gel
02/13/2012 BioSante Pharmaceuticals, Inc. to Present at BIO CEO & Investor Conference
02/09/2012 BioSante Pharmaceuticals Reports Positive LibiGel® Safety Data Review for Phase III Program
02/08/2012 BioSante Exchanges $5 Million Aggregate Principal Amount of Convertible Senior Notes for 6.7 Million Shares of Common Stock
01/31/2012 BioSante Pharmaceuticals Provides Corporate Update  

2011

12/14/2011 BioSante Pharmaceuticals Announces Results from LibiGel® Efficacy Trials
11/29/2011 BioSante Pharmaceuticals Announces Issuance of New LibiGel® Method of Use Patent
11/21/2011 BioSante Pharmaceuticals Added to NASDAQ Biotechnology Index
11/16/2011 BioSante Pharmaceuticals Announces Positive LibiGel® Pharmacokinetic Study Results
11/09/2011 BioSante Pharmaceuticals Reports Financial Results for Third Quarter 2011 and Pipeline Update
10/17/2011 BioSante Pharmaceuticals, Inc. to Present at BioCentury and BIO Healthcare Conferences
10/11/2011 BioSante Pharmaceuticals Reports Positive LibiGel® Safety Data Review in Phase III Program
10/04/2011 BioSante Pharmaceuticals Completes Both Pivotal LibiGel® Efficacy Trials
10/03/2011 BioSante Pharmaceuticals, Inc. to Present at Cancer Immunotherapy Conference
09/12/2011 BioSante Pharmaceuticals Successfully Completes LibiGel® Pharmacokinetic Study
09/01/2011 BioSante Pharmaceuticals, Inc. To Present at Three September Healthcare Conferences
08/02/2011 BioSante Pharmaceuticals Closes $48.0 Million Public Offering of Common Stock
07/28/2011 BioSante Pharmaceuticals Prices Public Offering of Common Stock
07/25/2011 BioSante Pharmaceuticals Reports Second Quarter 2011 Financial Results
07/21/2011 BioSante Pharmaceuticals Signs Melanoma Vaccine License
07/18/2011 BioSante Pharmaceuticals Announces Management Team Additions
06/07/2011 BioSante Pharmaceuticals, Inc. To Present at Jefferies Global Healthcare Conference
06/06/2011 BioSante Pharmaceuticals Announces Lifting of Clinical Hold on GVAX Prostate Cancer Vaccine
05/31/2011 BioSante Pharmaceuticals Completes Enrollment in LibiGel® Phase III Safety Study
05/18/2011 BioSante Pharmaceuticals, Inc. To Present at Two Upcoming Investor Conferences
05/10/2011 BioSante Pharmaceuticals Reports First Quarter Financial Results and Recent Developments
05/04/2011 BioSante Pharmaceuticals, Inc. to Present at JMP Securities Research Conference
04/27/2011 BioSante Pharmaceuticals, Inc. To Present at the Deutsche Bank Annual Health Care Conference
04/18/2011 BioSante Pharmaceuticals Announces Pancreatic and Prostate Cancer Vaccine License
04/13/2011 BioSante Pharmaceuticals Announces Teva New Drug Application for Bio-T-Gel™
04/11/2011 BioSante Pharmaceuticals, Inc. To Present at Future Leaders in the Biotech Industry Conference
04/04/2011 BioSante Pharmaceuticals to Host LibiGel® R&D; Event in New York City
03/30/2011 BioSante Pharmaceuticals Completes Enrollment in Both Pivotal LibiGel® Phase III Efficacy Trials
03/16/2011 BioSante Pharmaceuticals Reports Financial Results for 2010 and Clinical Development and Business Highlights
03/10/2011 BioSante Pharmaceuticals, Inc. to Present at Roth Annual Growth Stock Conference
03/09/2011 BioSante Pharmaceuticals Closes $25.1 Million Registered Direct Offering
03/04/2011 BioSante Pharmaceuticals to Raise $25.1 Million in Registered Direct Offering
03/03/2011 BioSante's Pancreas Cancer Vaccine Shows Survival Increase in Newly Published Study
02/24/2011 BioSante Pharmaceuticals Completes Enrollment in LibiGel® Phase III
Efficacy Trial
02/22/2011 BioSante Pharmaceuticals, Inc. to Present at the 2011 Citi Global Health
Care Conference
02/15/2011 BioSante Presents Data Showing Female Sexual Dysfunction is a Significant Unmet Medical Need
02/14/2011 BioSante Pharmaceuticals, Inc. To Present LibiGel® Safety Study Update At BIO CEO & Investor Conference
02/14/2011 BioSante Pharmaceuticals Reports Positive LibiGel® Safety Data in
Phase III Program
02/12/2011 BioSante Pharmaceuticals Reports Positive LibiGel® Safety Data in
Phase III Program
02/02/2011 BioSante Pharmaceuticals To Provide Update on LibiGel® Safety Study at ISSWSH Meeting
01/25/2011 BioSante Announces FDA Orphan Drug Designation for its Melanoma Cancer Vaccine
01/11/2011 BioSante Pharmaceuticals Confirms Female Sexual Dysfunction as an Unmet Medical Need

2010

12/31/2010 BioSante Pharmaceuticals Closes $18 Million Registered Direct Offering to Fund LibiGel® for Female Sexual Dysfunction
12/27/2010 BioSante Pharmaceuticals to Raise $18 Million in Registered Direct Offering
11/17/2010 BioSante Pharmaceuticals Sells Oncolytic Virus Technology to Cold Genesys, Inc.
11/12/2010 BioSante Pharmaceuticals Reports Third Quarter 2010 Financial Results
10/26/2010 BioSante Pharmaceuticals, Inc. to Present at Two Upcoming Investor Conferences
10/26/2010 BioSante Pharmaceuticals Reports Positive LibiGel® Data Monitoring Committee Recommendation
10/18/2010 BioSante Pharmaceuticals Reaches Key LibiGel® Safety Study Enrollment Target
10/14/2010 BioSante Pharmaceuticals To Present at Cancer Immunotherapy Conference
10/11/2010 BioSante Pharmaceuticals Presents LibiGel® Clinical Study Update at North American Menopause Society Meeting
10/04/2010 BioSante Pharmaceuticals, Inc. to Present LibiGel® Clinical Trial Update at North American Menopause Society Meeting
09/30/2010 BioSante Pharmaceuticals to Present at the Bio Investor Forum
09/22/2010 BioSante Pharmaceuticals, Inc. To Present at the JMP Healthcare Conference
09/07/2010 BioSante Pharmaceuticals, Inc. To Present at the Rodman & Renshaw Healthcare Conference
08/12/2010 BioSante Pharmaceuticals Reports Second Quarter 2010 Financial Results
07/13/2010 BioSante Pharmaceuticals Announces Initiation of LibiGel® Study to Evaluate its Effect on Cognitive Function in Women
06/30/2010 BioSante Pharmaceuticals Announces Positive Clinical Results In Pill-Plus™ Oral Contraceptive Study
06/28/2010 BioSante Pharmaceuticals Added to Russell 3000® Index
06/23/2010 BioSante Pharmaceuticals Closes $15 Million Registered Direct Offering to Fund LibiGel® for Female Sexual Dysfunction
06/21/2010 BioSante Pharmaceuticals to Raise $15 Million in Registered Direct Offering
06/21/2010 BioSante Pharmaceuticals Reports Positive LibiGel® Safety Data in Phase III Clinical Program
06/21/2010 BioSante Pharmaceuticals Says FDA Advisory Committee Recommendation Against Flibanserin has No Impact on LibiGel®
06/18/2010 BioSante Pharmaceuticals, Inc. To Present LibiGel® Safety Update at ENDO Annual Meeting
06/07/2010 BioSante Announces FDA Orphan Drug Designation for GVAX Chronic Myeloid Leukemia Cancer Vaccine
05/20/2010 BioSante Pharmaceuticals Announces Novartis' Successful Use of 2A/Furin Technology in Their Antibody Development Platform
05/17/2010 BioSante Pharmaceuticals Receives Two New Patents for Manufacture of Proteins, Including Antibodies
05/14/2010 BioSante Pharmaceuticals Reports Recent Developments and First Quarter Financial Results
05/12/2010 BioSante Pharmaceuticals, Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference
05/03/2010 BioSante Pharmaceuticals Announces Reinitiation of Prostate Cancer Vaccine Development
04/30/2010 BioSante Pharmaceuticals, Inc. to Present Cancer Vaccine Portfolio Update at the BIO International Convention
04/28/2010 BioSante Pharmaceuticals, Inc. to present at the Deutsche Bank Healthcare Conference
04/26/2010 BioSante Pharmaceuticals Enters Option Agreement to its 2A/Furin Antibody Expression Technology
04/19/2010 BioSante Pharmaceuticals, Inc. to Present and Participate in Cancer Immunotherapy Panel at the World Vaccine Congress
03/30/2010 BioSante Pharmaceuticals Reports Receipt of $2.16 Million in Elestrin™ Royalty Buydown, and Financial Results for 2009
03/23/2010 BioSante Announces Additional Positive Leukemia Vaccine Results and Second FDA Orphan Drug Designation
03/18/2010 BioSante Pharmaceuticals, Inc. and Rodman & Renshaw Announce Fireside Chat on Women's Health
03/15/2010 BioSante Announces FDA Orphan Drug Designation for GVAX Pancreatic Cancer Vaccine
03/10/2010 BioSante Announces Positive Leukemia Vaccine Results
03/09/2010 BioSante Pharmaceuticals Closes $18 Million in Registered Direct Offering
03/04/2010 BioSante Pharmaceuticals to Raise $18 Million in Registered Direct Offering
03/01/2010 BioSante Pharmaceuticals Receives Two New Patents for Manufacture of Proteins, Including Antibodies
02/22/2010 BioSante Pharmaceuticals Reports Positive LibiGel® Safety Data in
Phase III Program
02/18/2010 BioSante Pharmaceuticals, Inc. to Present LibiGel® Clinical Update at
ISSWSH Conference
02/16/2010 BioSante Pharmaceuticals Rated Among Top 15 Companies on The Biotechnology Patent Scorecard™ as published in The Wall Street Journal
02/09/2010 BioSante Pharmaceuticals Appoints Jeffrey Winkelman, Ph.D., J.D., Vice President, Oncology Programs
02/08/2010 BioSante Featured on the Med Tech Sentinal
02/03/2010 BioSante Pharmaceuticals, Inc. to Present at BIO CEO & Investor Conference
01/06/2010 BioSante Pharmaceuticals, Inc. to Present at OneMedForum and Biotech Showcase Conferences

2009

12/08/2009 BioSante Pharmaceuticals Monetizes a Portion of U.S. Elestrin™ Royalties
11/17/2009 BioSante Pharmaceuticals to Present at the Lazard Capital Markets Annual Healthcare Conference
11/16/2009 BioSante Pharmaceuticals Comments on Boehringer Ingelheim Clinical Test Results in Treatment of Female Sexual Dysfunction
11/10/2009 BioSante Pharmaceuticals to Present at Merriman Curhan Ford's Investor Summit
11/09/2009 BioSante Pharmaceuticals Reports Third Quarter 2009 Financial Results
10/29/2009 BioSante Pharmaceuticals to Present at the Oppenheimer Health Care Conference
10/22/2009 BioSante Pharmaceuticals to Present at the Bio Investor Forum
10/20/2009 BioSante Pharmaceuticals Reports Positive LibiGel® Safety Data in Phase III Program
10/14/2009 BioSante Pharmaceuticals and Cell Genesys Announce Completion of Merger
09/22/2009 BioSante Pharmaceuticals and Cell Genesys Announce Final Exchange Ratio for Merger
09/03/2009 BioSante Pharmaceuticals and Cell Genesys Announce September 30, 2009 Special Stockholders Meetings to Approve Merger
09/02/2009 BioSante Pharmaceuticals to Present at Upcoming Healthcare Conferences
08/17/2009 BioSante Pharmaceuticals Reports 100% Protection From H1N1 Challenge When Using BioVant™ Adjuvanted Vaccine
08/13/2009 BioSante Pharmaceuticals to Raise $12 Million in Registered Direct Offering
08/13/2009 BioSante Pharmaceuticals Reports Positive LibiGel® Safety Data in Phase III Program
06/30/2009 BioSante Pharmaceuticals and Cell Genesys Sign Definitive Merger Agreement
06/29/2009 BioSante Pharmaceuticals Comments on Study Showing No Increased Risk of Breast Cancer in Women Using Testosterone for Low Libido
06/25/2009 Paper in Journal of Sexual Medicine Cites Need for FDA-Approved Testosterone Treatment to Replace Growing Off-Label Use
06/23/2009 BioSante Pharmaceuticals Announces Elestrin™ NDA Submission in Israel
06/17/2009 BioSante Pharmaceuticals LibiGel® Safety Study to Continue Following Review by External Executive Committee
06/02/2009 BioSante Pharmaceuticals Comments on Benefits of Testosterone Use in HIV-Infected Women
05/14/2009 BioSante Pharmaceuticals to Present at The BIO International Conventio
05/11/2009 BioSante Pharmaceuticals Reports on First Quarter 2009 Financial Results and Swine Flu Activity
04/14/2009 BioSante Announces Launch of Elestrin™ in the U.S.
03/16/2009 BioSante Pharmaceuticals Reports LibiGel® Status and Financial
Results for 2008
02/17/2009 BioSante Pharmaceuticals, Inc. Presents LibiGel® Clinical and Market Information at ISSWSH Conference
02/05/2009 BioSante Pharmaceuticals, Inc. To Present At BIO CEO and Investor Conference and ISSWSH Conference
01/05/2009 BioSante Pharmaceuticals Announces Issuance of New Patent Covering Elestrin™

2008

12/17/2008 BioSante Pharmaceuticals Secures Committed Equity Financing Facility
12/08/2008 BioSante Pharmaceuticals Signs Elestrin™ Marketing Agreement with PharmaSwiss SA for Israel
12/04/2008 BioSante Pharmaceuticals Signs Elestrin™ Marketing Agreement with Azur Pharma
11/17/2008 BioSante Pharmaceuticals Announces Receipt of NIH Grant for Inhaled Interferon
11/11/2008 Testosterone Effective in Female Sexual Dysfunction, BioSante Conducting Long-Term Safety Study of LibiGel® in FSD
11/10/2008 BioSante Pharmaceuticals Reports Third Quarter 2008 Financial Results
10/31/2008 Stephen M. Simes, BioSante Pharmaceuticals President and CEO, To Present At Oppenheimer and Rodman & Renshaw Conferences
10/27/2008 Stephen M. Simes, BioSante Pharmaceuticals President and CEO, To Present At The BIO Investor Forum
10/22/2008 The Only Pharmaceutical Company with A Product In Active Phase III Development for Menopausal Women Experiencing Sexual Dysfunction
09/08/2008 BioSante Pharmaceuticals Announces Positive Oral Contraceptive Clinical Results
08/11/2008 BioSante Pharmaceuticals Reports Second Quarter 2008 Developments and Financial Results
08/07/2008 BioSante Pharmaceuticals Announces Reacquisition of Elestrin™, FDA Approved for Treatment of Hot Flashes
07/24/2008 BioSante Featured on TheStreet.com TV: Stephen M. Simes, CEO, Highlights Development Program for LibiGel®
07/16/2008 BioSante Pharmaceuticals Announces FDA Special Protocol Assessment (SPA) for Expanded Indication of LibiGel® in FSD
06/16/2008 Stephen M. Simes, BioSante Pharmaceuticals President and CEO, To Make Two Presentations At The BIO International Convention
06/12/2008 BioSante Pharmaceuticals VP of Clinical Development To Present at The Endocrine Society's 90th Annual Meeting
06/10/2008 BioSante Pharmaceuticals Engages Deutsche Bank As Its Strategic Advisor
05/14/2008 BioSante Pharmaceuticals to Present at Two International Health Care Conferences
05/09/2008 BioSante Pharmaceuticals Reports First Quarter 2008 Financial Results
05/012008 BioSante Pharmaceuticals to Present at Deutsche Bank Health Care Conference
04/15/2008 BioSante Pharmaceuticals Appoints Michael C. Snabes, M.D., PhD, Vice President, Clinical Development
03/19/2008 BioSante Pharmaceuticals Initiates Third LibiGel® Phase III Trial in the Treatment of Female Sexual Dysfunction under an SPA
03/17/2008 BioSante Pharmaceuticals Reports Product Development Highlights and 2007 Financial Results
03/03/2008 BioSante Pharmaceuticals to Present at the Susquehanna Healthcare Conference
02/06/2008 BioSante Pharmaceuticals to Discuss LibiGel® SPA in the Treatment of FSD, at BIO CEO and Investor Conference
01/29/2008 BioSante Pharmaceuticals Announces FDA Special Protocol Assessment (SPA) for LibiGel® in FSD
01/28/2008 BioSante Pharmaceuticals to Host Conference Call to Announce LibiGel® Special Protocol Assessment (SPA)
01/15/2008 BioSante Pharmaceuticals to Ring NASDAQ Closing Bell
01/07/2008 BioSante Pharmaceuticals Announces Initiation of LibiGel® (transdermal testosterone gel) Phase III Safety Study

2007

12/18/2007 BioSante Pharmaceuticals Receives Milestone Payment from Bradley Pharmaceuticals
12/05/2007 BioSante Pharmaceuticals to Present at Upcoming Medical and Investor Conferences
11/19/2007 BioSante Pharmaceuticals Announces License Agreement for its CaP Technology for Use in Aesthetic Medicinees
11/05/2007 BioSante Pharmaceuticals Common Stock Begins Trading On NASDAQ Global Market Today
11/02/2007 BioSante Pharmaceuticals Common Stock To Begin Trading On NASDAQ Global Market on Monday, November 5, 2007
11/01/2007 BioSante Pharmaceuticals Common Stock Approved for Listing on NASDAQ Global Market
10/23/2007 BioSante Pharmaceuticals Common Stock Approved for Listing on NASDAQ Global Market
10/02/2007 BioSante Pharmaceuticals to Present at Upcoming Conferences
09/17/2007 BioSante Pharmaceuticals to Present at Upcoming Conferences
09/11/2007 BioSante Pharmaceuticals Announces FDA Clarity on Development of LibiGel® (transdermal testosterone gel) in the Treatment of Female Sexual Dysfunction
09/10/2007 BioSante Pharmaceuticals to Host Conference Call Providing LibiGel® Clinical Development Update
09/05/2007 BioSante Pharmaceuticals Names Joy A. Thomas Vice President of Corporate Development
09/04/2007 BioSante Pharmaceuticals to Present at The Arch Investment Conference
08/14/2007 BioSante Pharmaceuticals Reports Second Quarter 2007 Financial Results
08/08/2007 BioSante Pharmaceuticals to Present at Upcoming Conferences
07/11/2007 BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
06/28/2007 BioSante Pharmaceuticals, Inc. Joins Russell Microcap Index
06/21/2007 New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, in Women aged 50-59 taking Estrogen Therapy, a Predictor of Cardiovascular Events
06/19/2007 BioSante Pharmaceuticals Announces Oral Contraceptive Phase II Study Initiation
06/14/2007 BioSante Pharmaceuticals Completes $18.3 Million Private Placement of Common Stock
06/13/2007 BioSante Pharmaceuticals Announces the Commercial Launch of Elestrin™
06/12/2007 BioSante Pharmaceuticals Announces Reinitiation of Product Development With Teva
05/30/2007 BioSante Pharmaceuticals to Present at Upcoming Conferences
05/25/2007 BioSante Pharmaceuticals Announces $16.5 Million Private Placement of Common Stock
05/16/2007 BioSante Pharmaceuticals to Present at Upcoming Conferences
05/07/2007 BioSante Pharmaceuticals Signs Oral Contraceptive License with Pantarhei Bioscience
05/02/2007 BioSante Pharmaceuticals to Present at Upcoming Conferences
05/01/2007 BioSante Pharmaceuticals Reports First Quarter 2007 Financial Results
04/10/2007 BioSante Pharmaceuticals Announces Issuance of New Patent Covering Elestrin™ and LibiGel®
03/26/2007 BioSante Pharmaceuticals Receives Milestone Payment from Bradley Pharmaceuticals
03/09/2007 BioSante Pharmaceuticals Reports Product Development Highlights and 2006 Financial Results
03/08/2007 BioSante Pharmaceuticals to Present at Upcoming Conferences
03/08/2007 BioSante Pharmaceuticals Reports Net Profit of $2.8 million for 2006 And Investor Conference Call
03/01/2007 Lowest FDA-Approved Dosage of Estradiol to Significantly Reduce Hot Flashes Reported in Newly-Published Study
02/21/2007 BioSante Pharmaceuticals to Present LibiGel® at International Society for the Study of Women's Sexual Health (ISSWSH) Annual Meeting
02/12/2007 BioSante Pharmaceuticals Announces Presentation/Webcast at the BIO CEO & Investor Conference
02/07/2007 BioSante Pharmaceuticals Announces Notice of Allowance of ElestrinT Patent by U.S. Patent & Trademark Office
01/30/2007 BioSante Pharmaceuticals Announces Positive Bird Flu Results Using Proprietary Vaccine Adjuvant in Pre-Clinical Study

2006

12/28/2006 BioSante Pharmaceuticals Initiates Phase III Study of LibiGel® (transdermal testosterone gel) in the Treatment of Female Sexual Dysfunction
12/18/2006 BioSante Pharmaceuticals Receives FDA Approval of Bio-E-Gel® (estradiol gel), to be Marketed as ElestrinT
12/04/2006 BioSante Pharmaceuticals to Present at Upcoming Biotech/Specialty Pharma and Investor Conferences
11/13/2006 BioSante Pharmaceuticals Reports Third Quarter 2006 Financial Results and Reviews Bio-E-Gel® Marketing Agreement
11/08/2006 BioSante Pharmaceuticals Signs Bio-E-Gel® Marketing Agreement with Bradley Pharmaceuticals, Inc
11/03/2006 BioSante Pharmaceuticals to Present at Rodman & Renshaw 8th Annual Healthcare Conference
10/16/2006 BioSante Pharmaceuticals to Present at 2006 BIO InvestorForum
10/12/2006 BioSante Pharmaceuticals Presents Bio-E-Gel® Woman-to-Partner Transfer Study at Menopause Society Meeting
10/11/2006 BioSante Pharmaceuticals Presents Bio-E-Gel® Data at North American Menopause Society Meeting
09/25/2006 BioSante Pharmaceuticals to Present at UBS Global Life Sciences Conference
08/14/2006 BioSante Pharmaceuticals ReportsSecond Quarter 2006 Financial Results
07/24/2006 BioSante Pharmaceuticals Closes $7.6 Million Private Placement of Common Stock
07/10/2006 BioSante Pharmaceuticals Announces $7.6 Million Private Placement of Common Stock
06/15/2006 BioSante Pharmaceuticals to Present at Needham Conference
05/12/2006 BioSante Pharmaceuticals Reports Product Development Highlights and First Quarter 2006 Financial Results
05/10/2006 BioSante Pharmaceuticals to Present Bio-E-Gel¨ and Corporate Overview at Rodman & Renshaw Global Healthcare Conference
05/08/2006 BioSante Pharmaceuticals to Present Positive Study Results for Potential Adjuvanted Bird Flu Vaccine at 9th Annual Conference on Vaccine Research
04/24/2006 BioBioSante Pharmaceuticals Announces Positive Study Resultsfor Potential Adjuvanted Bird Flu Vaccine
04/19/2006 BioSante Pharmaceuticals Announces FDA Filing and Review of NDA for Bio-E-Gel®;
04/17/2006 BioSante Pharmaceuticals Comments on New Data from Women's Health Initiative Study Showing No Increased Risk of Breast Cancer with Estrogen-Alone Therapy
04/10/2006 BioSante Pharmaceuticals, Inc. to Present at BIO Annual International Convention on April 11 in Chicago
03/31/2006 BioSante Pharmaceuticals Reports Product Development Highlights and Financial Results for 2005
03/22/2006 BioSante Pharmaceuticals Presents New Anthrax Vaccine Data at World Vaccine Congress
03/06/2006 BioSante Pharmaceuticals to Present at International Society for the Study of Women's Sexual Health and Sachs Biotech Conferences
02/27/2006 BioSante Pharmaceuticals Signs Option and License for its CaP Technology for Use in Aesthetic Medicine
02/21/2006 BioSante Pharmaceuticals Comments on New Data from Women's Health Initiative Study Showing No Increased Coronary Heart Risk with Estrogen-Alone Therapy
02/16/2006 BioSante Pharmaceuticals Announces Bio-E-Gel® NDA Submissione
02/13/2006 BioSante Pharmaceuticals to Participate on Panel at BIO CEO & Investor Conference
02/06/2006 BioSante Pharmaceuticals Announces Subcontract with the University of Nebraska-Lincoln Using its Proprietary CaP™ Drug Delivery System
01/09/2006 BioSante Pharmaceuticals Strengthens Management and Reaffirms Bio-E-Gel® NDA Filing Guidance

2005

12/12/2005 BioSante Pharmaceuticals to Present at NYSSA Biotech/Specialty Pharma Conference
12/05/2005 BioSantePharmaceuticals to Present at Informed Investors Biotechnology and Healthcare Forum
11/03/2005 BioSante Pharmaceuticals to Present at Rodman & Renshaw Techvest Healthcare Conference
11/02/2005 BioSante Pharmaceuticals Comments on Updated FDA Guidance for Testosterone Therapy
10/25/2005 BioSante Pharmaceuticals to Present Today at C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference
10/18/2005 BioSante Pharmaceuticals Honors World Menopause Day
10/17/2005 BioSante Pharmaceuticals to Present at BIO InvestorForum
09/29/2005 BIOSANTE ANNOUNCES FIRST TRANSDERMAL ESTRADIOL GEL WITH 3 DOSES THAT SIGNIFICANTLY DECREASE HOT FLASHES IN MENOPAUSAL WOMEN
09/27/2005 BioSante Pharmaceuticals to Present at UBS Global Life Sciences Conference
09/21/2005 BioSante Encouraged by FDA Panel on Exubera, Superior Results of Own Inhaled Insulin Study
09/14/2005 BioSante Pharmaceuticals Signs License Option Agreement with European Pharmaceutical Company
09/13/2005 BioSante Pharmaceuticals to Present at Wall Street Reporter Small-Cap Discovery Conference
08/12/2005 BioSante Pharmaceuticals Reports Product Development Highlights and Second Quarter 2005 Financial Results
08/10/2005 BioSante Pharmaceuticals Licenses Contraceptive Technology From Wake Forest University
07/06/2005 BioSante Pharmaceuticals Announces Bio-E-Gel® (estradiol gel) Significantly Reduces Hot Flashes in Menopausal Women
06/21/2005 BioSante Pharmaceuticals to Present at William Blair & Company Growth Stock Conference
06/16/2005 BioSante Pharmaceuticals to Present at BIO 2005 Conference
05/19/2005 BioSante Pharmaceuticals to Present at UBS Global Pharmaceuticals Conference
05/18/2005 BioSante Pharmaceuticals Presents CaP Nanotechnology Review at International Conference on Immunopotentiators in Modern Vaccines
05/16/2005 BioSante Pharmaceuticals Reports Product Development Highlights and First Quarter 2005 Financial Results
05/03/2005 BioSante Announces CaP Manufacturing Agreement and Progress in Protein Delivery
05/02/2005 BioSante Pharmaceuticals to Present at Rodman & Renshaw Techvest Global Healthcare Conference
04/19/2005 BioSante Pharmaceuticals Presents New Anthrax Vaccine Data at World Vaccine Congress
04/04/2005 BioSante Pharmaceuticals Completes Pivotal Phase III Clinical Trial for Estrogen Gel
03/30/2005 BioSante Pharmaceuticals Comments on NIH Conference Panel Statement on Estrogen Therapy for Menopausal Women
03/28/2005 BioSante Pharmaceuticals Announces 2004 Key Achievements and Financial Results
03/14/2005 BioSante Pharmaceuticals to Present at Sachs-Bloomberg Biotech Forum
02/28/2005 BioSante Pharmaceuticals to Present at Leerink Swann Healthcare Conference
02/22/2005 BioSante Pharmaceuticals Announces Panel Presentation/Webcast At the 7th Annual BIO CEO & Investor Conference
01/18/2005 BioSante Pharmaceuticals Completes Enrollment in Pivotal Phase III Clinical Trial for Estrogen Gel